BridgeBio Pharma, Inc. EBITDA Margin

EBITDA Margin of BBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA Margin growth rates and interactive chart.


Highlights and Quick Summary

  • EBITDA Margin for the quarter ending September 30, 2022 was -37713.31% (a 35288.3% increase compared to previous quarter)
  • Year-over-year quarterly EBITDA Margin increased by 2861.67%
  • Annual EBITDA Margin for 2021 was -818.73% (a -85.67% decrease from previous year)
  • Annual EBITDA Margin for 2020 was -5714.56% (a 770.58% increase from previous year)
  • Annual EBITDA Margin for 2019 was -656.41% (a -Infinity% decrease from previous year)
  • Twelve month EBITDA Margin ending September 30, 2022 was -611.24% (a -1.69% decrease compared to previous quarter)
  • Twelve month trailing EBITDA Margin decreased by -25.34% year-over-year
Trailing EBITDA Margin for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
-611.24% -621.72% -811.36% -818.73%
Visit stockrow.com/BBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA Margin of BridgeBio Pharma, Inc.

Most recent EBITDA Marginof BBIO including historical data for past 10 years.

Interactive Chart of EBITDA Margin of BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -37713.31% -106.57% -10141.32%
2021 -1273.38% -6366.64% -167.57% -36133.77% -818.73%
2020 -104142.62% -1488.3% 0.0% 0.0% -5714.56%
2019 -569.06% -203.93% 0.0% 0.0% -656.41%
2018 0.0% 0.0%
2017 0.0%

Business Profile of BridgeBio Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology